Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Amro M. Abdelrahman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9865-0551; OpenAlex author ID A5080312157. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 14

  1. Epigenetic context defines the transcriptional activity of canonical and noncanonical NF-κB signaling in pancreatic cancer. Co-author DOI 10.1038/s41420-026-03019-9↗
  2. KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival. Co-author DOI 10.1126/sciadv.aea2106↗
  3. Therapeutic targeting of FOSL1 and RELA-dependent transcriptional mechanisms to suppress pancreatic cancer metastasis. Co-author DOI 10.1038/s41419-025-07810-x↗
  4. Glucocorticoid receptor suppresses GATA6-mediated RNA polymerase II pause release to modulate classical subtype identity in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-334374↗
  5. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  6. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer. First author DOI 10.1097/xcs.0000000000001059↗
  7. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14875-5↗
  8. In vivo label-free optical signatures of chemotherapy response in human pancreatic ductal adenocarcinoma patient-derived xenografts. Co-author DOI 10.1038/s42003-023-05368-y↗
  9. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. First author DOI 10.1136/gutjnl-2022-328154↗
  10. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  11. Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. First author DOI 10.1016/j.hpb.2022.06.005↗
  12. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  13. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  14. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… Co-author DOI 10.1016/j.jamcollsurg.2021.05.009↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 14 shared papers, 2021–2026 · strength 2.45
  2. Steven A. Johnsen · 6 shared papers, 2023–2026 · strength 1.20
  3. Jennifer A. Yonkus · 8 shared papers, 2021–2025 · strength 1.12
  4. Roberto Alva‐Ruiz · 7 shared papers, 2021–2025 · strength 0.96
  5. Sean Patrick Cleary · 6 shared papers, 2021–2025 · strength 0.88
  6. Michael L. Kendrick · 6 shared papers, 2021–2025 · strength 0.88
  7. Joana E. Aggrey-Fynn · 4 shared papers, 2023–2026 · strength 0.77
  8. Travis Edward Grotz · 5 shared papers, 2021–2025 · strength 0.75
  9. Zeynab Najafova · 4 shared papers, 2023–2026 · strength 0.69
  10. Jennifer L. Leiting · 4 shared papers, 2021–2025 · strength 0.59
  11. Danielle Marie Carlson · 3 shared papers, 2024–2025 · strength 0.59
  12. Thomas L. Ekstrom · 3 shared papers, 2023–2026 · strength 0.56
  13. Rondell Patrell Graham · 4 shared papers, 2022–2023 · strength 0.51
  14. Susanne Gray Warner · 3 shared papers, 2022–2025 · strength 0.51
  15. Cornelius A. Thiels · 3 shared papers, 2022–2025 · strength 0.51
  16. Xin Wang · 3 shared papers, 2023–2025 · strength 0.45
  17. Jochen Gaedcke · 3 shared papers, 2023–2025 · strength 0.45
  18. Ana P. Kutschat · 3 shared papers, 2023–2025 · strength 0.45
  19. Elisabeth Heßmann · 3 shared papers, 2023–2025 · strength 0.45
  20. Robert R. McWilliams · 3 shared papers, 2022–2025 · strength 0.44
  21. Ajit Harishkumar Goenka · 2 shared papers, 2022–2024 · strength 0.33
  22. Stephan A. Hahn · 2 shared papers, 2023 · strength 0.27
  23. Feda H. Hamdan · 2 shared papers, 2023 · strength 0.27
  24. Jens Thomas Siveke · 2 shared papers, 2023 · strength 0.27
  25. Thorvardur Ragnar Halfdanarson · 2 shared papers, 2022 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.